Immunotherapy

Kiromic Biopharma, Inc. Shareholder Notificaiton: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Kiromic Biopharma, Inc. (KRBP)

Retrieved on: 
Wednesday, August 17, 2022 - 11:37pm
Steps, FDA, Drug Quality and Security Act, Intelligence, Securities Exchange Act of 1934, Patient, Company, NASDAQ, Inc., KRBP, Immunotherapy, Securities Act of 1933, IPO, Complaint, Person, Medical device

If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here .

Key Points: 
  • If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here .
  • Rather than disclosing this information, Kiromic represented that clinical testing was expected to proceed in the third quarter of 2021.
  • However, clinical testing did not proceed in the third quarter 2021, nor was it likely given the FDA's imposition of a clinical hold.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Retrieved on: 
Wednesday, August 17, 2022 - 1:00pm
U.S. Securities and Exchange Commission, Medicine, Survival, Risk, Tams, Metastasis, Injection, GLOBE, Neoplasm, Population, Private Securities Litigation Reform Act, Yale Cancer Center, IP, Cancer, PMID, Security (finance), Annual report, MOH, Marketing, Patient, Therapy, Stage 2, Ministry, Safety, Macrophage, Decision-making, Sepsis, Immunotherapy, Nasdaq, Ovarian cancer, Human, Progression-free survival, Immunosuppression, Animal, Immune system, JAMA Network Open, Adult, Pharmaceutical industry, Medical device, Health

We aim to build on these results in our upcoming Phase I/II trial and are pleased that the Israeli Ministry of Health has cleared it for initiation.

Key Points: 
  • We aim to build on these results in our upcoming Phase I/II trial and are pleased that the Israeli Ministry of Health has cleared it for initiation.
  • The planned Phase I/II trial is a multicenter, open-label, dose escalation trial that is expected to enroll up to 48 patients with advanced solid tumors across two trial stages.
  • Stage 2 will evaluate escalating doses of Allocetra administered IV or IP and combined with anti-PD1 therapy.
  • Patients in Stage 2 will receive three injections of Allocetra concomitantly with the studied anti-PD1 agent.

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

Retrieved on: 
Wednesday, August 17, 2022 - 12:00pm
Executive, Foralumab, Safety, Mab, GLOBE, Patient, Technology, Immunotherapy, Fine chemical, Pharmaceutical industry

NEW YORK, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (Tiziana or the Company), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 20,000 common shares at $0.75 per share.

Key Points: 
  • NEW YORK, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (Tiziana or the Company), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 20,000 common shares at $0.75 per share.
  • Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.
  • Tizianas innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery.
  • Tizianas technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia

Retrieved on: 
Wednesday, August 17, 2022 - 12:00pm
U.S. Securities and Exchange Commission, Narendran, Dermatology, Physiology, Molecular biology, Hematology, Cumming School of Medicine, Evaluation, Drug discovery, NIH, Forward-looking statement, Legislation, GLOBE, IL, SEC, Microbiology, Pharmacology, Medicine, National, Security (finance), Research, Science Publishing Group, Epson HX-20, Company, P.O, WNK1, Dimer, Virology, Safety, Doctor of Philosophy, OTCQB, Immunotherapy, Completeness, Ophthalmology, University, MD, HX, Biochemistry, Association, Pharmaceutical industry, Risk management, Pediatrics, Oncology

The Companys innovatively-assembled and proprietary rose bengal is the lead member of a class of small molecules called halogenated xanthenes.

Key Points: 
  • The Companys innovatively-assembled and proprietary rose bengal is the lead member of a class of small molecules called halogenated xanthenes.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes (HXs).
  • Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements.
  • Risks, uncertainties, and assumptions include those discussed in the Companys filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:

Mallinckrodt plc Provides Update on Executive Committee

Retrieved on: 
Wednesday, August 17, 2022 - 11:46am
U.S. Securities and Exchange Commission, Corporate integrity agreement, Quality, Social, National Executive Committee of the Labour Party, Science, Government Affairs Institute, Analgesic, Autoimmunity, SVP, Board on Science, Technology, and Economic Policy, SEC, Private Securities Litigation Reform Act, Ajman Specialty General Hospital, Leadership, Growth, Director, Board, Annual report, ESG, The Company, Chapter 11, Title 11, United States Code, Patient, General manager, Executive Committee, Company, EVP, Hikma Pharmaceuticals, Corporation, Program, Neurology, Corporate development, VP, Operation, Risk, Nephrology, Immunotherapy, Technology, Business operations, Commercial, Rheumatology, Ophthalmology, Biophysical environment, Patient advocacy, Management, Medicine, Mallinckrodt

DUBLIN, Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today provided an update on its Executive Committee.

Key Points: 
  • DUBLIN, Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today provided an update on its Executive Committee.
  • "Mallinckrodt is at an important inflection point, and the leaders of our go-forward Executive Committee will join me in guiding the business and further strengthening our focus on the patients we serve," said Mr. Olafsson.
  • For full biographies of each member of the Executive Committee, please visit https://www.mallinckrodt.com/about/executive-committee/ .
  • Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies.

Mallinckrodt Announces Appointment of Karen Ling to Its Board of Directors

Retrieved on: 
Wednesday, August 17, 2022 - 11:45am
Expansion, U.S. Securities and Exchange Commission, Wyeth, Senior, Analgesic, Autoimmunity, Private Securities Litigation Reform Act, SEC, Leadership, Bajaj Consumer Care, Board, Ajman Specialty General Hospital, Annual report, The Company, American International Group, Financial compensation, Boston University, Patient, The Jed Foundation, Company, Acquisition, Human resources, Neurology, Allergan, AIG, Risk, Nephrology, Company secretary, Immunotherapy, Board of directors, Professional Football Compensation Committee, Rheumatology, Yale University, Ophthalmology, The, Economics, Organization, Management, Medicine, Merck, Mallinckrodt

DUBLIN, Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Karen Ling has been appointed to the Company's Board of Directors, effective August 12, 2022.

Key Points: 
  • DUBLIN, Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Karen Ling has been appointed to the Company's Board of Directors, effective August 12, 2022.
  • With the addition of Ms. Ling, the Mallinckrodt Board will expand to eight directors, seven of whom are independent.
  • "We are thrilled to welcome a leader of Karen's caliber to the Mallinckrodt Board," said Paul Bisaro, Chairman of the Mallinckrodt Board of Directors.
  • "I have great admiration for the work Mallinckrodt does to serve patients, and I am honored to join Mallinckrodt at such an important time for the Company," said Ms. Ling.

ROSEN, A TOP RANKED LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

Retrieved on: 
Tuesday, August 16, 2022 - 7:53pm
Titan, FDA, Investigational New Drug, GLOBE, TO, Food and Drug Administration Amendments Act of 2007, Facebook, IND, Advertising, Kirom Bukhoroi, Court, Company, Twitter, I-Space (Chinese company), WHY, NASDAQ, Immunotherapy, LinkedIn, THE, IPO, Food, Insurance, Tobacco, Pharmaceutical industry

WHAT TO DO NEXT: To join the Kiromic BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=8051 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kiromic BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=8051 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

The Worldwide Non-Small Cell Lung Cancer Treatment Industry is Expected to Reach $25.7 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 16, 2022 - 3:22pm
Pharmaceutical, Health, Oncology, Smoker, Lung cancer, Cancer, Death, Sinonasal undifferentiated carcinoma, Incidence, Hospital, Patient, Cell, COVID-19, Large-cell lung carcinoma, Projection, Awareness, Adenocarcinoma, CAGR, Immunotherapy, Squamous-cell carcinoma of the lung, Squamous cell carcinoma, Asbestos, Adoption, Uranium, Pharmaceutical industry, NSCLC

The non-small cell lung cancer subtype accounts for most lung cancer cases (NSCLC).

Key Points: 
  • The non-small cell lung cancer subtype accounts for most lung cancer cases (NSCLC).
  • As a result of the expanding frequency and incidence of non-small cell lung cancer across all demographics and age categories, demand for non-small cell lung cancer therapies has increased.
  • Non-Small Cell Lung Cancer Treatment (NSCLC) Market represented a central challenge in clinical diagnosis and therapy decision-making in the context of the favorably contagious COVID-19 pandemic.
  • The rise of the non-small cell lung cancer therapy (NSCLC) market has been fuelled by the increased number of non-small cell lung cancer diagnoses and increased awareness in developed and emerging countries.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Carvana, and Kiromic and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, August 16, 2022 - 2:00am
FDA, P.C, Bankruptcy, Disclosure, Documentation, Risk, NYSE, Â, GLOBE, Georgetown University Law Center, Technology, Ecosystem, Coinbase, SEC, Bloomberg, IND, Chemistry (relationship), Texas Law Review, Kirom Bukhoroi, Prospectus, Lists of schools in England, Company, Credit risk, Complaint, Register, NASDAQ, Immunotherapy, News, Offering, IPO, Cryptocurrency, Security (finance), Renewable energy, Audit, Pharmaceutical industry, Carvana

Coinbase provides financial infrastructure and technology products and services for the cryptocurrency economy (or cryptoeconomy) in the U.S. and internationally.

Key Points: 
  • Coinbase provides financial infrastructure and technology products and services for the cryptocurrency economy (or cryptoeconomy) in the U.S. and internationally.
  • Following this disclosure, the price of Coinbases Class A common stock fell $19.27 per share, or 26.4%, to close at $53.72 per share on May 11, 2022.
  • For more information on the Kiromic class action go to: https://bespc.com/cases/KRBP
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers

Retrieved on: 
Monday, August 15, 2022 - 9:05pm
FDA, Cell, U.S. Securities and Exchange Commission, CRS, Cancer, Forward-looking statement, GLOBE, Technology, Private Securities Litigation Reform Act, SEC, Infection, IND, Security (finance), NEXI, Environment, Research, Annual report, AML, Patient, Company, JDRF, GAAP, Degenerative disease, Immunotherapy, Investigational New Drug, Nanoparticle, Food and Drug Administration, Multiple myeloma, Yale University, Nasdaq, AIM, Toxicity, Food, GVHD, Terminology, Neurotoxicity, Pharmaceutical industry, Risk management, Vaccine, Medical imaging

We will provide an update on these early programs through the end of year.

Key Points: 
  • We will provide an update on these early programs through the end of year.
  • Research and development expenses were $11.8 million in the second quarter of 2022, compared to $8.1 million for the same period in the prior year.
  • Forward-looking statements represent the Companys beliefs and assumptions only as of the date of this press release.
  • Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements.